Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 10/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 10/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.38 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12026412 | 0.83 | PDK4 (0.51) | PDK4GRM5GRM1NAMPTTNK2 | |
| SCHEMBL18852698 | 0.81 | PDK4 (0.47) | PDK4GRM5GRM1NAMPTTNK2 | |
| SCHEMBL12931062 | 0.79 | ADORA1 (0.53) | PDK4GRM5ADORA1GRM1NAMPT | |
| SCHEMBL6750186 | 0.79 | PDK4 (0.46) | PDK4GRM5ADORA1GRM1NAMPT | |
| SCHEMBL5369547 | 0.78 | GAA (0.41) | — | |
| SCHEMBL23852710 | 0.78 | ADORA1 (0.45) | PDK4GRM5ADORA1GRM1NAMPT | |
| SCHEMBL19995874 | 0.77 | ADORA1 (0.46) | PDK4GRM5ADORA1GRM1NAMPT | |
| SCHEMBL31397205 | 0.77 | GRM5 (0.50) | PDK4GRM5GRM1 | |
| SCHEMBL5392226 | 0.76 | PDK4 (0.46) | PDK4GRM5ADORA1GRM1NAMPT | |
| SCHEMBL3151019 | 0.76 | GAA (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102395578-A | Compounds for the treatment of metabolic disorders | PROSIDION LTD | 2012-03-28 | — | — | CN | disclosed |
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FFAR2, GPBAR1 | PDK4 430/4885GRM5 462/4885ADORA1 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.